ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive: We thereafter compare the leading approach of drug selection in CML treatment (relative IC50, see section 2) with methods that include further information (such as Abl1 inhibitor concentration data) to assess their ability to infer drug resistance, which would better inform choices in treatment when resistant mutations arise.